Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: A phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, Emily Figueiredo Neves Yuki, Tatiana do Nascimento Pedrosa, Solange Fusco, Priscila T. Rojo, Rosa Maria Rodrigues Pereira, Samuel Katsuyuki Shinjo, Danieli Andrade, Percival D. Sampaio‐Barros, Carolina Torres Ribeiro, Giordano B. H. Deveza, Victor A. O. Martins, Clóvis A. Silva, Marta Heloísa Lopes, Alberto J. S. Duarte, Leila Antonângelo, Éster Cerdeira Sabino, Esper G. Kallás, Sandra Gofinet Pasoto, Eloísa Bonfá
Abstract
CoronaVac has an excellent safety profile and induces moderate IgG seroconversion and neutralizing antibodies in the majority of patients with ARD.
Topics & Concepts
ImmunogenicityMedicineImmunologyVirologyAntibodySARS-CoV-2 and COVID-19 ResearchIntramuscular injections and effectsHeparin-Induced Thrombocytopenia and Thrombosis